Sareum Holdings PLC Japan and Singapore Patent Grants
17 October 2016 - 5:00PM
RNS Non-Regulatory
TIDMSAR
Sareum Holdings PLC
17 October 2016
(AIM: SAR) 17 October 2016
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Japan and Singapore Patent Grants for Sareum's Aurora+FLT3
Kinase Inhibitors
Sareum (AIM: SAR), the specialist cancer drug discovery and
development business, is pleased to announce that the Japan and
Singapore Patent Offices have issued notifications that patents
will be granted for inventions associated with Sareum's Aurora+FLT3
kinase inhibitor programme.
These patents(*) describe compounds that inhibit the activity of
Aurora and FLT3 kinase enzymes and the medical use of these
compounds, particularly in the treatment of cancer. The granting of
this patent in Japan means that Sareum will now have approved
patent protection in all major territories for its Aurora+FLT3
kinase inhibitor programme. The Company announced that similar
patents were to be granted in the USA and Europe in September 2015
and in China in August 2016.
Sareum's Aurora+FLT3 kinase inhibitor programme targets acute
myeloid leukaemia (AML) and other leukaemias and lymphomas. In
disease models of AML, the preclinical development candidate
molecule demonstrates greater than 98% tumour inhibition.
Preclinical development studies to obtain approval for human
clinical trials are being undertaken in collaboration with, and
funded by, Hebei Medical University Biomedical Engineering Center
(HMUBEC) in China.
* Japanese Patent Application no. 2014-555250, Singapore Patent
Application no. 11201404277W
Sareum's CSO, Dr John Reader, commented: "These notifications of
patent grants in Japan and Singapore complete the protection of the
intellectual property associated with Sareum's Aurora+FLT3
programme in all the major territories, enhancing our negotiating
position with potential licence partners".
For further information:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / Nick Prowting 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce / William Lynne 020 3764 2341/2342
The Communications Portfolio
(Sareum Media enquiries)
Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk 07785 922 354
Notes for editors:
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease, for licensing to pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum operates an outsourced research model, working with
international collaborators and a world-wide network of research
providers. Its most advanced programme (Chk1) commenced clinical
trials in May 2016 and was licensed to NASDAQ-listed ProNAi
Therapeutics in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug
discovery technology platform that has so far produced the
Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease
research programmes, which are in the IND-enabling preclinical and
lead optimisation stages respectively. SKIL(R) can also generate
drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the symbol SAR. For further
information, please visit www.sareum.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAKQDKABDDAKD
(END) Dow Jones Newswires
October 17, 2016 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024